/

The Prix Galien Canada – Product Innovation Award

Presented to a drug that has made the most significant overall contribution to patient care in Canada.

Overview

The Prix Galien Canada – Innovative Product Award is presented every year to the company that has developed a drug product launched on the Canadian market and judged by the Jury to have made the most significant overall contribution to patient care in Canada in terms of efficacy, safety, benefits and innovation.

Call for submissions for the 2024 Prix Galien Canada Innovative Product Award is now open. Please review the submission and eligibility requirements below. Applications will be accepted until August 2, 2024. To submit a nomination, please download and complete the form and send to wdeen@imc-mnc.ca.

Submission

The Prix Galien Canada – Innovative Product Award will be presented to a drug, launched at least 12 months ago and no more than 60 months (5 years) ago, that has made the most significant overall contribution to patient care in Canada, according to the Jury of Prix Galien Canada.

  • The product is considered a “break-through” rather than a derivative of an already existing agent
  • The product has made a most significant overall contribution to patient care in Canada in terms of efficacy, safety, benefits, and innovation
  • The product has a major impact on standards of care

If applicable, the candidate will detail the Canadian contribution to the discovery and/or development of the product and to the contribution to publications related to the product.

Eligibility

For the purpose of Prix Galien Canada, the Jury will use the definition of “drug” in the Food and Drug Act. “Drug” includes any substance or mixture of substances manufactured, sold or represented for use in:

  1. The diagnosis treatment, mitigation or prevention of a disease, a disorder, an abnormal physical state or the symptoms thereof, in humans and animals;
  2. Restoring, correcting or modifying organic functions in humans or animals;
  3. Disinfection in premises in which food is manufactured, prepared or kept.

It must be stressed that to be considered, the drug product must bear a Drug Identification Number (D.I.N.)

Prix Galien Canada guarantees that all information will be held in strict confidentiality and will be available only to parties involved in the adjudication of the award.

Submissions

Applications should not exceed fourteen (14) pages, and must include:

  • The completed submission form signed by an authorized Officer of the Company.
  • A cheque in the amount of $2500 (plus applicable taxes) made out to the Health Research Foundation.
  • Five (5) published original articles including no more than one review article may also be submitted as an Appendix.

Featured Resources

Prix Galien Canada – Product Innovation Award Submission Form

The Prix Galien Canada – Innovative Product Award will be presented to a drug, launched at least 12 months ago and no more than 60 months (5 years) ago, that has made the most significant overall contribution to patient care in Canada, according to the Jury of Prix Galien Canada.

View

Jury

The Jury of the Prix Galien Canada is composed of eminent specialists involved in the sphere of Canadian and Pharmaceutical Research. The Jury is completely independent and its decisions are final.

Dr. Ernesto L. Schiffrin – Chair of the Jury

Distinguished James McGill Professor, Department of Medicine, McGill University,

Director, Hypertension and Vascular Research Unit, Lady Davis Institute for Medical Research,

Director, Cardiovascular Prevention Centre and

Physician-in-Chief Emeritus, Sir Mortimer B. Davis-Jewish General Hospital

Dr. Helen Burt

Associate Vice President Research & International at UBC

Angiotech Professor of Drug Delivery in the Faculty of Pharmaceutical Sciences at UBC

Dr. Brian O’Rourke

Chair, HTA Steering Committee, Centre for Innovation in Regulatory Science (CIRS)

Member of the Scientific Advisory Council, Centre for Innovation in Regulatory Science (CIRS)

President, Professional Society for Health Economics and Outcomes Research (ISPOR)

Colonel Commandant (Honorary), Royal Canadian Medical Service

Emeritus Member, Canadian Health Leadership Network

Dr. Jill M. Sanders Award of Excellence in Health Technology Assessment

Former President and CEO, CADTH

Dr. Chantal Pharand

Associate Vice-Rector, Student Affairs and Success,

Prix Pharmacien de cœur et d’action en recherche

AFPC-Janssen Innovation in Education Award,

ACCP-Rhone-Poulenc Rorer Cardiovascular Research Award

Université de Montréal

Fellow Ordre des pharmaciens du Québec

Dr. Kishor M. Wasan

Kishor M. Wasan, R.Ph., Ph.D., FAAPS, FCAHS, FCSPS

Fellow Canadian Academic of Health Sciences

Fellow, American Association of Pharmaceutical Sciences

Distinguished University Scholar & Adjunct Professor

Co-Director/Co-Founder, Neglected Global Diseases Initiative-UBC

Department of Urologic Sciences Faculty of Medicine The University of British Columbia

Chief Medical and Scientific Officer, Skymount Medical US Inc.

Former Dean and Retired Professor, University of Saskatchewan

Dr. Don Weaver

Neurologist and medicinal chemist at the Krembil Research Institute, University Health Network, University of Toronto

Queen’s University

Dalhousie University

PhD in organic chemistry

Co-founder, Neurochem Inc. and Treventis Corp.

His research is focused on the design and development of new chemical entities for the treatment of Alzheimer’s disease

Previous winner of the Prix Galien Canada prize

Laureates

2023

Pfizer-BioNTech
Comirnaty (COVID-19 Vaccine, mRNA)

2022

Takeda Canada Inc.
Takhzyro (lanedelumab injection)

2020

Alnylam Pharmaceuticals and Medicago
Patisiran (ONPATTRO)

2019

GSK
Dr. Susan George, Dr. Brian O’Dowd, Dr. Gregory A. Demopulos, Dr. George A. Gaitanaris, Dr. Alexander Gragerov
SHINGRIX (Recombinant Zoster Vaccine)

2018

Novartis Pharmaceuticals Canada Inc.
SACUBITRIL/VALSARTAN (Entresto)

2017

Merck Canada
Dr. Ernesto Schiffrin (McGill University)
KEYTRUDA (pembrolizumab)

2016

Gilead Sciences Canada and Takeda Canada
Dr. Philip F. Halloran OC, MD, PhD, FRCPC, FRSC
HARVONI (Sofosbuvir/Ledipasvir) Gilead Sciences Canada
ENTYVIO (Vedolizumab) Takeda Canada

2015

Boehringer-Ingelheim Canada
Dr. John Kelton, Dr. Theodore Warkentin
Afatinib (Giotrif)

2014

Roche and InterMune Canada
Dr. Brett Finlay (University of British Columbia)
PIRFENIDONE (ESBRIET)

2013

Bristol Myers Squibb Canada
Dr. Francis Allan Plummer (University of Manitoba)
YERVOY (IPILIMUMAB)

2012

Vertex Canada Ltd and Merck Canada Inc.
Dr. Robert E. W. Hancock (University of British Columbia)
INCIVEK (TELAPREVIR) Vertex Canada
VICTRELIS (BOCEPRIVIR) Merck Canada Ltd.

2011

Boehringer Ingelheim Canada
Dr. Pieter R. Cullis (University of British Columbia)
PRADAX

2010

Janssen-Ortho
Dr. Julio S. G. Montaner (BC Center for Excellence in HIV/AIDS)
STELARA 

2009

Pfizer Canada inc.
Dr. Donald F. Weaver (University of Dalhousie)
CHAMPIX 

2008

Merck Frosst Canada
Dr. Daniel J. Drucker (University of Toronto)
GARDASIL

2007

Dr. Michael Hayden (University of British Columbia)

2006

Dr. Harold Jennings (National Research Council Canada)

2005

Dr. Lorne Babiuk (University of Sakatchewan)  

2004

Boehringer Ingelheim Canada
Dr. Paul Armstrong (Faculty of medicine, University of Alberta)
SPIRIVA

2003

Novartis Pharma Canada
Dr. Mark A. Wainberg (Jewish General Hospital – Sir Mortimer B. Davis)
GLEEVEC

2002

Wyeth-Ayerst Canada
Drs. Julia Levy and David Dolphin (University Of British Columbia) and (Ex Aequo) Dr Anthony J. Pawson (University Of Toronto)
ENBREL

2001

Pfizer
Dr. Salim Yusuf (Research Centre of the Hamilton Civic Hospital)
VIAGRA

2000

Merck Frosst Canada
Montelukast Sodium Research Team
SINGULAIR

1999

Parke-Davis Canada
Dr. Jack Hirsh (Research Centre of the Hamilton Civic Hospital)
LIPITOR

1998

Merck Frosst Canada
Drs. Lorne Tyrrell and Morris Robins (University Of Edmonton, Alberta)
FOSAMAX

1997

Discovered by BioChem Pharma et développé par Glaxo Wellcome
Drs. Serge Gauthier, Judes Poirier and Rémi Quirion (Mcgill University and Research Centre of the Douglas Hospital)
3TC

1996

Marion Merrell Dow
Antiviral Compounds Research Team (Biochem Pharma)
SABRIL

1995

Janssen Pharmaceutical
Dr. Peter Schiller (IRCM)
RISPERDAL

1994

Glaxo Canada
Drs. Philip Seeman, Hyman Niznik and Hubert Van Tol (University Of Toronto)
IMMITREX

Contact

Prix Galien Canada

Health Research Foundation (HRF) of Innovative Medicines Canada
55 Metcalfe Street, Suite 1220, Ottawa, Ontario K1P 6L5

Wilma Deen, Executive Director, Health Research Foundation (HRF)
wdeen@imc-mnc.ca

International Contact:
secretarygeneral@prixgalien.com

resources

Discover. Learn.
Understand.

Informative content to keep you up to date on the most pressing issues facing our industry.